Protocol Ledger

NCT07188025 · Phase III · RECRUITING

ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

Interventional Phase III clinical trial protocol NCT07188025 sponsored by Erasmus Medical Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-14 Enrollment: 103 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07188025
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)103 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07188025
Protocol FieldVerified Registry Value
NCT IdentifierNCT07188025
Consolidated Lead SponsorErasmus Medical Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment103 participants (ESTIMATED)
Registered Start Date2025-10-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07188025
Hospital Research SiteLocationSite Profile
Amsterdam UMCAmsterdam, NetherlandsOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI